Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445023 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
A Phase 3 study of Chronic Spontaneous Urticaria, sponsored by Celldex Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 963
- Enrollment target
- 20
- Study locations
NCT06445023 is a Phase 3 study of Chronic Spontaneous Urticaria that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 963 participants, below the 1,374-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06445023, a Phase 3 study of Chronic Spontaneous Urticaria, is active but no longer recruiting, sponsored by Celldex Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 963 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Conditions Studied
Interventions
- BIOLOGICAL barzolvolimab
- BIOLOGICAL Matching placebo
Study Locations (20)
California
- First OC Dermatology - Fountain Valley - Fountain Valley
- 310 Clinical Research - Inglewood
- Dermatology Research Associates - Los Angeles
- Focus Clinical Research - Los Angeles - Los Angeles
- Cura Clinical Research - Oxnard
- Allergy and Asthma Consultants - Redwood City
- Acclaim Clinical Research - San Diego
- West Dermatology Research Center - San Diego
- Therapeutics Clinical Research - San Diego
- Orso Health, Inc. - Torrance
- Integrated Research of Inland, Inc. - Upland
Florida
- Encore Medical Research Boynton Beach - Boynton Beach
- Direct Helpers Research Center - Hialeah
- GSI Clinical Research - Margate
- International Dermatology Research Inc - Miami - Miami
- Miami Dade Medical Research Institute, LLC - Miami
- Sarasota Clinical Research - Sarasota
- GCP Global Clinical Professionals, LLC - St. Petersburg
Alabama
- Cahaba Dermatology Skin Health Center - Birmingham
Colorado
- Western States Clinical Research Inc - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 963 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445023
The ClinicalTrials.gov registry entry for NCT06445023 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 963 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,374-participant average among 18 other Chronic Spontaneous Urticaria trials with a reported enrollment target (30% lower). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Spontaneous Urticaria appearing as the primary indexed condition, and to 2 interventions - of which barzolvolimab is the first listed.
NCT06445023 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06445023 about?
NCT06445023 is a clinical study titled "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria". The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
What is the current status of trial NCT06445023?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 963 participants. The study started on 2024-07-11. Estimated completion is 2027-04.
What conditions does trial NCT06445023 study?
This clinical trial studies the following conditions: Chronic Spontaneous Urticaria.
What interventions are being tested in trial NCT06445023?
The interventions under investigation include: barzolvolimab (BIOLOGICAL), Matching placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06445023?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445023 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Spontaneous Urticaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
RECRUITING · Phase 3
-
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
RECRUITING · Phase 3
-
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
ACTIVE NOT RECRUITING · Phase 3
-
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
ACTIVE NOT RECRUITING · Phase 3
-
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
COMPLETED · Phase 3
-
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.